Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Cogent Biosciences ( (COGT) ) is now available.
On September 5, 2025, Cogent Biosciences entered into a lease agreement with BP THIRD AVENUE LLC for a new corporate headquarters in Waltham, Massachusetts. The lease covers 31,518 square feet and is expected to commence in May 2026, with a term of nearly eight years and an option for a five-year extension. This move is part of Cogent’s strategic operations, potentially impacting its market positioning by providing a purpose-built space without significant tenant improvement costs.
The most recent analyst rating on (COGT) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.
Spark’s Take on COGT Stock
According to Spark, TipRanks’ AI Analyst, COGT is a Underperform.
Cogent Biosciences is currently facing significant financial difficulties, with no recent revenue, ongoing operating losses, and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio and absence of dividends. These factors contribute to the lowest overall stock score, highlighting substantial risks for investors.
To see Spark’s full report on COGT stock, click here.
More about Cogent Biosciences
Cogent Biosciences is a company operating in the biotechnology industry, focusing on developing targeted therapies to treat genetically driven diseases.
Average Trading Volume: 2,796,806
Technical Sentiment Signal: Buy
Current Market Cap: $1.78B
See more insights into COGT stock on TipRanks’ Stock Analysis page.